BRAF and plasma cell neoplasm: From a cohort of 217 patients with plasma cell neoplasm that underwent NGS mutation profiling, we identified 68 (31.3%) patients who had mutations in RAS signaling pathway genes (KRAS, NRAS or BRAF) and no other mutations.